Mon. 4 Mar 2024, 6:42am ET
Benzinga
Biotech, News, Health Care, General
- Complete Remission rate of 64% and Overall Response Rate of 73% demonstrated in highly refractory patients
- Durability of clinical activity achieved 67% Overall Survival and 42% Progression Free Survival at One Year